Partners

Our International Network of Partners

We are incredibly grateful for the committed engagement of our many partners across Alberta, Canada, and the world which makes meeting our ambitious goals possible.

map

Medical Institutions

Alberta Health Services (Alberta)

CHUM Groupe de soutien du cancer de la prostate (Montreal)

London Regional Cancer Program (London, ON)

Northern Alberta Urology Centre (Edmonton)

Prostate Cancer Centre (Calgary)

The Prostate Centre at The Princess Margaret Hospital (Toronto)

Vancouver Prostate Cancer Centre (Vancouver)

Technology Platforms

APOGEE (UK)

BGI Genomics (China)

Malvern (UK)

Nanosight

Precision Nanosystems (BC)

Universities

Case Western Reserve University (Cleveland, OH)

Dalhousie University (Halifax, NS)

Fraunhofer ITEM-R (Regensburg, Germany)

University of Alberta (Edmonton, AB)

University of Calgary (Calgary, AB)

University of Toronto (Toronto, ON)

Vanderbilt University (Nashville, TN)

Western University (London, ON)

Biorepositories

Alberta Cancer Research Biobank (Calgary, Edmonton)

Australian Prostate Cancer BioResource (Australia: Melbourne, Sydney, Brisbane and Adelaide)

Biosample Hub

Canadian Biosample Repository

Canadian Prostate Cancer Biomarker Network

OICR Tumour Bank (Ontario)

Tomorrow Project 

UHN GU BioBank

Financial Resources

Alberta Cancer Foundation (Alberta)

Alberta Innovates Health Solutions – Collaborative Research and Innovation opportunities

Alberta Lymphedema Network (Edmonton, Alberta)

Movember Foundation (Australia, Canada)

Motorcycle Ride for Dad (Canada)

Prostate Cancer Canada

University Hospital Foundation – J & J Partnership

Support Groups

Prostate Cancer Canada Network (Canada)

Prostate Cancer Canada Network (Calgary)

Prostate Cancer Canada Network (Edmonton)

Terry Fox Research Institute (Canada)

Business Partners

Nanostics Inc

Dr. Nawaid Usmani and team receive funding for their PRIME study!

The PRIME Study – Prevention and Intervention for MEtabolic syndrome:

Androgen deprivation therapy (ADT), and newer manipulations of androgen receptor signaling have improved outcomes for advanced prostate cancer (PCa) patients.  The toxicities of ADT are many, including an increased risk of developing metabolic syndrome (MS; defined as at least 3 of: hyperglycemia; abdominal obesity; hypertriglyceridemia; reduced HDL cholesterol; and/or hypertension). MS is associated with an increased risk of diabetes, cardiovascular disease mortality, stroke mortality, and all-cause mortality.  The prevalence of MS in men receiving ADT is at least 50% and contributes to decreased quality of life and increased non-cancer-related mortality.  Metformin holds promise as a countermeasure to MS development, and also has been shown to suppress PCa growth in pre-clinical models.

We hypothesize that the addition of metformin to ADT will reduce the rates of MS in men with advanced PCa, diminishing important toxicities of a therapy universally used in advanced disease.

We propose a double-blind, randomized phase III study of metformin or placebo in men with PCa starting intermittent ADT. The primary endpoint is the difference in MS rates at 1 year.  Other aims include evaluation of the influence of metformin on: individual MS components at additional time points; mean serum insulin levels and measures of insulin resistance; weight and quality of life.

A finding that metformin reduces MS incidence and/or has other benefits would change practice, as it would provide a practical and inexpensive strategy to reduce toxicity of an intervention employed in most men with advanced PCa.

- Catalina Vasquez